Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy

Specificaties
Gebonden, blz. | Engels
Elsevier Science | e druk, 2021
ISBN13: 9780323853231
Rubricering
Elsevier Science e druk, 2021 9780323853231
€ 188,50
Levertijd ongeveer 8 werkdagen

Samenvatting

Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.

Specificaties

ISBN13:9780323853231
Taal:Engels
Bindwijze:Gebonden

Inhoudsopgave

<p>1. An introduction to CRISPR-Cas systems for reprogramming of the genome of mammalian cells<br>2. CRISPR-Cas systems for genome editing of mammalian cells<br>3. Genome-wide detection and analysis of CRISPR-Cas off-targets<br>4. CRISPR-based diagnostics for detection of pathogens<br>5. Creating cell lines for mimicking diseases<br>6. Modulating Cas9 activity for precision gene editing<br>7. Crispr-Cas9 in cancer therapeutics<br>8. CRISPR-Cas9 for treating heredity diseases<br>9. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals<br>10. Recent advances in stem cells & gene editing: Drug discovery and therapeutics<br>11. Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms<br>12. Genome editing in cardiovascular diseases<br>13. CRISPR/Cas9 in epigenetics studies of health and disease<br>14. Patents, ethics, biosafety and regulation using CRISPR technology</p>
€ 188,50
Levertijd ongeveer 8 werkdagen

Rubrieken

    Personen

      Trefwoorden

        Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy